Death by a thousand cuts
Sharp, thorny plants for the unsuspecting visitor at the Vizcaya museum, Miami
In the fiercely competitive race to develop new treatments for metastatic castrate resistant prostate cancer (mCRPC), biotech companies must present compelling data to stand out from the pack.
However, as a recent example from Janux Therapeutics demonstrates, a closer look under the hood often reveals more spin than substance.
In this article, we’ll dissect Janux’s claims about their bispecific PSMA T cell engager JANX-007, and expose how cherry picking and selective data presentation can skew and even misrepresent a therapy’s true potential.
Read on to learn the red and green flags to watch out for and why extraordinary claims require extraordinary evidence…
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
